Patents by Inventor Robert McKay

Robert McKay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140275207
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Sanjay K. Pandey, Robert McKay, Sanjay Bhanot, Xing-Xian Yu
  • Patent number: 8791083
    Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: July 29, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
  • Patent number: 8673871
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: March 18, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 8642753
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 4, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie, Robert McKay, Sanjay Bhanot
  • Patent number: 8586554
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: November 19, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 8580948
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: November 12, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Robert McKay, Sanjay K. Pandey
  • Publication number: 20130109849
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 2, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Brett P. Monia, John G. Geisler, Robert McKay, Kenneth W. Dobie
  • Patent number: 8372967
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: February 12, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20130030036
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Application
    Filed: June 22, 2012
    Publication date: January 31, 2013
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
  • Patent number: 8362232
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 29, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 8322732
    Abstract: A portable workstation includes wheels, a tabletop, a generally planar member and a chassis joining the wheels, the tabletop and the planar member. While joined to the wheels and the tabletop by the chassis, the planar member is movable between a protracted position and a retracted position. A majority of the planar member extends above the tabletop in the protracted position, and a majority of the planar member does not extend above the tabletop in the retracted position.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: December 4, 2012
    Assignee: BradyQuin, LLC
    Inventors: Jodi McKay, Robert McKay, Brett Rhinehardt, Daniel Lee Bizzell, Ian D. Kovacevich, Tom Philpott
  • Patent number: 8299041
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: October 30, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Brett P. Monia, John G. Geisler, Robert McKay, Kenneth W. Dobie
  • Publication number: 20120208864
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 16, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 8227593
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: July 24, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Robert McKay, Sanjay K. Pandey
  • Patent number: 8202981
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: June 19, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
  • Patent number: 8188059
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: May 29, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20120115930
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
    Type: Application
    Filed: November 10, 2011
    Publication date: May 10, 2012
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: BRETT P. MONIA, C. FRANK BENNETT, WILLIAM A. GAARDE, TRISHA LOCKHART, ROBERT MCKAY
  • Publication number: 20120077862
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: July 6, 2011
    Publication date: March 29, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madelline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie
  • Patent number: 8143230
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: March 27, 2012
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric Swayze, Edward Wancewicz
  • Patent number: D662569
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: June 26, 2012
    Assignee: Coverguardian, Inc.
    Inventors: Donald Robert McKay, Darrell Edward Fletcher